Evergreen Wealth Management LLC Lowers Holdings in Johnson & Johnson (NYSE:JNJ)

Evergreen Wealth Management LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,994 shares of the company's stock after selling 2,623 shares during the quarter. Johnson & Johnson accounts for 1.9% of Evergreen Wealth Management LLC's investment portfolio, making the stock its 21st largest holding. Evergreen Wealth Management LLC's holdings in Johnson & Johnson were worth $3,181,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also bought and sold shares of JNJ. IFS Advisors LLC grew its stake in Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after purchasing an additional 100 shares during the period. Highline Wealth Partners LLC bought a new position in Johnson & Johnson in the 3rd quarter valued at $31,000. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson in the 4th quarter valued at $32,000. RPg Family Wealth Advisory LLC bought a new position in Johnson & Johnson in the 3rd quarter valued at $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC grew its stake in Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after purchasing an additional 91 shares during the period. Institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on JNJ shares. Leerink Partners reduced their price objective on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a research note on Thursday, January 23rd. Barclays increased their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a research note on Tuesday, January 28th. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Wells Fargo & Company cut their price target on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Finally, Morgan Stanley cut their price target on Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average price target of $170.67.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded up $2.67 on Friday, hitting $162.35. The company's stock had a trading volume of 12,540,171 shares, compared to its average volume of 9,073,381. The company has a 50-day simple moving average of $148.61 and a 200 day simple moving average of $155.89. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a market capitalization of $390.87 billion, a PE ratio of 24.41, a PEG ratio of 2.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same period last year, the firm posted $2.29 EPS. Johnson & Johnson's revenue for the quarter was up 5.3% compared to the same quarter last year. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.06%. Johnson & Johnson's payout ratio is 74.59%.

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.